Description
DS8201-772 Destiny Ovarian-01 A Phase 3, Open-label, Multicenter, Randomized Study of Trastuzumab ENGOT Ov89 Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First- line Maintenance Therapy in HER2-Expressing Ovarian Cancer
Study details
For detailed information on this trial, please click here
Trial status
Opening March 2026
Location
Principal Investigator
Dr. Rene Roux
You are leaving our website
You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.